MedTrace Logo

A Comparison of Three Different Modalities in Improving Oral Hygiene

NCT04386421 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2020-11-06

No results posted yet for this study

Summary

The objective of the study is to compare effectiveness of OHI modalities a. verbal vs videographic material, b. Verbal vs plaque disclosing tablet and c. Videographic material vs plaque disclosing tablet over 3 months in adult orthodontic patients undergoing Fixed Appliance Treatment (FAT). Secondary objective of this study is to evaluate influence of three different modalities on patient cooperation and compliance towards orthodontic treatment.

Conditions

  • Oral Disease

Interventions

OTHER

Video on oral hygeine instructions

A 3 minute video will be shown providing information regarding the care of the dentition during Fixed appliance treatment along with the importance of patient compliance and cooperation. The video will also be showing the consequences of poorly followed instructions such as gingivitis and white spot lesions.

DRUG

Plaque disclosing tablets

Plaque disclosing tablets: Product: 2-Tone Disclosing Tablets Young Dental Manufacturing 13705 Shoreline Court East Earth City, MO 63045 Composition: Flavor, SD Tutti Fruiti 1 %, D and C Red 1 % and FD and C Blue 1 %

Sponsors & Collaborators

  • Aga Khan University

    lead OTHER

Principal Investigators

  • Rashna Hoshang Sukhia, BDS, FCPS · Aga Khan University and Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-01
Primary Completion
2021-08-30
Completion
2021-08-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04386421 on ClinicalTrials.gov